NASDAQ : MBRX
Moleculin Biotech, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 8.72 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.49M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.98M |
| Enterprise Value | 1.01M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 973,869 |
| Shares Outstanding | 973,869 |
| Shares Change (YoY) | +906.89% |
| Shares Change (QoQ) | +37.73% |
| Owned by Insiders (%) | 6.69% |
| Owned by Institutions (%) | 2.45% |
| Float | 838,699 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.24 |
| P/TBV Ratio | 17.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.94 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -671.51 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,371.64% |
| Return on Assets (ROA) | -84.57% |
| Return on Invested Capital (ROIC) | -703.03% |
| Return on Capital Employed (ROCE) | -245.24% |
| Weighted Average Cost of Capital (WACC) | 15.13% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.91M |
| Employee Count | 17 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.00 |
| 52-Week Price Change | -96.48% |
| 50-Day Moving Average | 10.77 |
| 200-Day Moving Average | 40.00 |
| Relative Strength Index (RSI) | 46.26 |
| Average Volume (20 Days) | 44,641 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 126,324 |
| Short Previous Month | 204,583 |
| Short % of Shares Out | 12.97% |
| Short % of Float | 15.06% |
| Short Ratio (days to cover) | 0.12 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.88M |
| Pretax Income | -30.33M |
| Net Income | -32.53M |
| EBITDA | -28.83M |
| EBIT | -28.88M |
| Earnings Per Share (EPS) | -$191.95 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 7.26M |
| Total Debt | 292,000 |
| Net Cash | 6.97M |
| Net Cash Per Share | $7.16 |
| Equity (Book Value) | 11.59M |
| Book Value Per Share | 32.64 |
| Working Capital | -590,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -25.36M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 47,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -25.36M |
| FCF Per Share | -$26.04 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -906.89% |
| Shareholder Yield | -906.89% |
| Earnings Yield | -2,343.66% |
| FCF Yield | -329.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $240.00 |
| Price Target Difference | 2,830.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |